⏱ News is delayed by 15 minutes. Sign in for real-time access.
Sign in
TVRD News
Tvardi Therapeutics, Inc. Common Stock
Form 8-K
sec.gov
TVRD
Tvardi Therapeutics Announces Third Quarter 2026 Results and Provides Business Update
globenewswire.com
TVRD
Tvardi Therapeutics to Participate in Chardan’s 10th Annual Healthcare Conference
globenewswire.com
TVRD
New Preclinical Data Further Support Potential for Tvardi’s STAT3 Inhibitors in Ulcerative Colitis (UC)
globenewswire.com
TVRD
Tvardi Therapeutics to Participate in Upcoming Investor Events
globenewswire.com
TVRD
Form 8-K
sec.gov
TVRD
Tvardi Therapeutics Announces Second Quarter 2026 Results and Provides Business Update
globenewswire.com
TVRD
Tvardi Therapeutics to Host KOL Webinar on the Clinical Potential of TTI-109 in Ulcerative Colitis (UC) and the Evolving Treatment Landscape, on August 19, 2026
globenewswire.com
TVRD
Form 8-K
sec.gov
TVRD
Tvardi Therapeutics Selects Ulcerative Colitis as Initial Indication for TTI-109
globenewswire.com
TVRD